Patents Assigned to Cancer Advances, Inc.
-
Publication number: 20230398196Abstract: Provided are methods for enhancing anti-tumor and/or anti-cancer immunotherapies. In some embodiments, the methods include administering to a subject in need thereof a composition that includes a conjugate that includes a gastrin immunogen conjugated to an immunogenic carrier, optionally conjugated via a linker, in an amount and via a route sufficient to enhance entry into the tumor and/or cancer of an anti-tumor T cell, whereby an anti- and/or anti-cancer tumor immunotherapy is enhanced. Also provided are pharmaceutical compositions that have the conjugates for use in treating tumors and cancers, methods for treating tumors and/or cancers, and methods for sensitizing solid tumors and/or cancers in subjects to chimeric antigen receptor-T (CAR-T) cell therapies.Type: ApplicationFiled: November 8, 2021Publication date: December 14, 2023Applicants: Cancer Advances Inc., Georgetown UniversityInventors: Allen Cato, Lynda Sutton, Jill P. Smith
-
Publication number: 20230086898Abstract: Provided are methods for sensitizing gastrin-associated tumors and/or cancers in subjects to inducers of humoral and cellular immune responses. In some embodiments, the methods relate to administering compositions that have anti-gastrin antibodies, gastrin peptides, and/or nucleic acids that inhibit expression of gastrin gene products to subjects. Also provided are methods for preventing, reducing, and/or eliminating the formation of fibroses associated with tumors and/or cancers, and methods for treating gastrin-associated tumors and/or cancers that include administering to subjects in need thereof a first agent that provides and/or induces an anti-gastrin humoral or cellular immune response in the subject and a second agent that includes one or more stimulators of cellular immune responses against the tumors and/or cancers.Type: ApplicationFiled: November 18, 2022Publication date: March 23, 2023Applicant: Cancer Advances Inc.Inventors: Lynda Sutton, Jill P. Smith, Nicholas Osborne, Brian E. Huber, Allen Cato
-
Patent number: 11583576Abstract: Provided are methods for sensitizing gastrin-associated tumors and/or cancers in subjects to inducers of humoral and cellular immune responses. In some embodiments, the methods relate to administering compositions that have anti-gastrin antibodies, gastrin peptides, and/or nucleic acids that inhibit expression of gastrin gene products to subjects. Also provided are methods for preventing, reducing, and/or eliminating the formation of fibroses associated with tumors and/or cancers, and methods for treating gastrin-associated tumors and/or cancers that include administering to subjects in need thereof a first agent that provides and/or induces an anti-gastrin humoral or cellular immune response in the subject and a second agent that includes one or more stimulators of cellular immune responses against the tumors and/or cancers.Type: GrantFiled: June 15, 2018Date of Patent: February 21, 2023Assignee: Cancer Advances Inc.Inventors: Lynda Sutton, Jill P. Smith, Nicholas Osborne, Brian E. Huber, Allen Cato
-
Publication number: 20210275649Abstract: Provided are methods for preventing initiation and/or progression of gastrin-associated tumors and/or cancers in subjects. In some embodiments, the methods relate to administering compositions that gastrin immunogens to subjects. Also provided are methods for inhibiting development of gastrin-associated precancerous lesions, methods for preventing formation of fibrosis associated with a tumor and/or a cancer, uses of compositions that include a gastrin immunogen to prevent initiation and/or development of a gastrin-associated tumor or cancer and/or for preparing medicaments therefor, and compositions for use in preventing initiation and/or development of gastrin-associated tumors and/or cancers and/or precancerous lesions thereof.Type: ApplicationFiled: January 13, 2021Publication date: September 9, 2021Applicant: Cancer Advances Inc.Inventors: Lynda Sutton, Jill P. Smith, Allen Cato, Teresa Phillips
-
Publication number: 20200206332Abstract: Provided are methods for sensitizing gastrin-associated tumors and/or cancers in subjects to inducers of humoral and cellular immune responses. In some embodiments, the methods relate to administering compositions that have anti-gastrin antibodies, gastrin peptides, and/or nucleic acids that inhibit expression of gastrin gene products to subjects. Also provided are methods for preventing, reducing, and/or eliminating the formation of fibroses associated with tumors and/or cancers, and methods for treating gastrin-associated tumors and/or cancers that include administering to subjects in need thereof a first agent that provides and/or induces an anti-gastrin humoral or cellular immune response in the subject and a second agent that includes one or more stimulators of cellular immune responses against the tumors and/or cancers.Type: ApplicationFiled: June 15, 2018Publication date: July 2, 2020Applicant: Cancer Advances Inc.Inventors: Lynda Sutton, Jill P. Smith, Nicholas Osborne, Brian E. Huber, Allen Cato
-
Patent number: 8808695Abstract: The present invention provides progastrin-binding molecules that are useful therapeutically for passive immunization against progastrin in gastrin-promoted diseases or conditions. The progastrin-binding molecules are specific for progastrin but do not bind gastrin-17(G17), gastrin-34(G34), glycine-extended gastrin-17(G17-Gly) or glycine-extended gastrin-34(G34-Gly). The progastrin-binding molecules include monoclonal antibodies (MAbs) selective for sequences at the N-terminus and the C-terminus of the gastrin precursor molecule, progastrin.Type: GrantFiled: February 28, 2012Date of Patent: August 19, 2014Assignee: Cancer Advances, Inc.Inventor: Stephen Grimes
-
Patent number: 8388966Abstract: A combination for use in the treatment of pancreatic cancer comprising: (i) an anti-gastrin effective immunogenic composition; and, (ii) one or more chemotherapeutic agents suitable for inhibiting cancer growth.Type: GrantFiled: August 8, 2008Date of Patent: March 5, 2013Assignee: Cancer Advances, Inc.Inventors: Philip C. Gevas, Dov Michaeli, Stephen Grimes, Martyn Caplin
-
Patent number: 8343930Abstract: The present invention relates to a combination therapy method for treating gastrin-dependent tumors. The method comprises the immunization of a patient with an anti-gastrin 17 immunogenic composition in combination with the administration of chemotherapeutic agents such as 5-fluorouracil and leucovorin.Type: GrantFiled: January 25, 2010Date of Patent: January 1, 2013Assignee: Cancer Advances, Inc.Inventors: Philip C. Gevas, Stephen Grimes, Stephen L. Karr, Susan A. Watson, Dov Michaeli
-
Patent number: 8158128Abstract: The present invention provides progastrin-binding molecules specific for progastrin that do not bind gastrin-17(G17), gastrin-34(G34), glycine-extended gastrin-17(G17-Gly), or glycine-extended gastrin-34(G34-Gly). Further, the invention provides monoclonal antibodies (MAbs) selective for sequences at the N-terminus and the C-terminus of the gastrin precursor molecule, progastrin and the hybridomas that produce these MAbs. Also provided are panels of Mabs useful for the detection and quantitation of progastrin and gastrin hormone species in immuno-detection and quantitation assays. These assays are useful for diagnosing and monitoring a gastrin-promoted disease or condition, or for monitoring the progress of a course of therapy. The invention further provides solid phase assays including immunohistochemical (IHC) and immunofluorescence (IF) assays suitable for detection and visualization of gastrin species in solid samples, such as biopsy samples or tissue slices.Type: GrantFiled: September 21, 2005Date of Patent: April 17, 2012Assignee: Cancer Advances, Inc.Inventor: Stephen Grimes
-
Patent number: 7964371Abstract: The invention provides assay methods for the detection and quantitation of gastrin hormones, including total and free gastrin hormone in a sample. ELISA-type heterogeneous phase assays suitable for use with biological fluid samples such as blood, plasma or other bodily fluids of a mammal, particularly a human subject are provided. The method provides a precise assay for the amounts of free and total G17 and G34 in biological fluid samples, as well as the amounts of free and total Gly-extended G17, and Gly-extended G34. Also provided are methods of determining suitable treatment for patient suffering from a gastrin hormone-mediated disease or condition employing gastrin hormone immunoassays.Type: GrantFiled: May 7, 2007Date of Patent: June 21, 2011Assignee: Cancer Advances, Inc.Inventors: Stephen Grimes, John Little, Lorraine McLoughlin
-
Publication number: 20110117108Abstract: The invention relates to the treatment and/or prevention of cancerous and/or, precancerous conditions of the liver, lung and esophagus by actively and/or passively immunizing a patient against the peptide hormone gastrin and/or a gastrin receptor, e.g., the CCK-B/gastrin receptor. The immunizations of the invention may be employed as a monotherapy, an adjunctive therapy, or as part of a combination therapy.Type: ApplicationFiled: January 24, 2011Publication date: May 19, 2011Applicant: Cancer Advances, Inc.Inventors: Philip C. Gevas, Dov Michaeli, Stephen Grimes